EMA Authorised: Alyftrek (deutivacaftor;tezacaftor;vanzacaftor calcium dihydrate) — Vertex Pharmaceuticals (Ireland) Limited

View source ↗

Summary

EMA authorised Alyftrek, a triple combination cystic fibrosis medicine (deutivacaftor/tezacaftor/vanzacaftor calcium dihydrate) by Vertex Pharmaceuticals (Irela…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ALYFTREK (VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR)

Snippet

Status: Authorised. Therapeutic area: Cystic Fibrosis. MAH: Vertex Pharmaceuticals (Ireland) Limited. Decision date: 30/03/2026. Orphan medicine